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The discovery, isolation, and successful
clinical application of interferons marked
a new era of biotechnology and medicine
(Pestka et al., 1987). Discovery of the
interferons originated from study of viral
interference: how infection with one virus
inhibited infection by another.The protein
p53 was discovered during research on
the virus SV40 (Thomas et al., 1983).
Both the interferons and p53 have now
earned a place in understanding the
mechanisms of oncogenesis and in
developing therapy for cancers. p53 is a
tumor suppressor. Once activated, the
p53 protein acts as a transcriptional reg-
ulator by binding to the promoter DNAs
of various target genes that mediate its
actions. For example, p53 induces
expression of protein p21, which in turn
directly blocks cell division by interaction
with cdk2, a protein stimulating cell divi-
sion. Mutations of p53 are found in most
tumors; these mutations do not permit
p53 to bind to DNA to establish the can-
cer-killing cascade in tumor cells. IFN-α,
IFN-β, and IFN-γ have been found to
have significant roles and pathways to
induce apoptosis (Clemens, 2003). In
the past ten years, a number of reports
have begun to relate interactions of inter-
ferons (IFNs) and p53. Because both the
tumor suppressor p53 and the interfer-
ons exhibit antioncogenic activity,
Takaoka et al. (2003) asked if there is a
link between p53 and the interferons in
oncogenesis. They examined the effects
of IFN-α and IFN-β on p53 expression
and activity and the effects of p53 on the
actions of IFN-α and IFN-β and demon-
strated that there is a link between the
interferons (IFN-α and IFN-β) and p53
(Takaoka et al., 2003), a conclusion also
made by others (Mecchia et al., 2000).
Takaoka et al. (2003) demonstrated
that p53 can be induced by IFN-α and
IFN-β. Mouse embryo fibroblasts (MEF)
and human hepatoma cancer cell lines
HepG2 and HLE treated with IFN-β
showed an increase in the p53 protein.
The p53 mRNA was induced about 3-
fold with IFN-β in MEF but not in MEF
from IRF-9−/− mice, consistent with the
requirement for the intact IFN-activated
transcription factor ISGF3 (Stat1, Stat2,
and IRF-9) for induction. Two interferon-
stimulated response elements (ISRE)
were identified in the p53 gene. An anti-
Stat2 antibody was used for chromatin
immunoprecipitation from cells treated
with IFN-β; both p53-ISREs were found.
Therefore, IFN-β induces transcriptional
activation of the p53 gene through the
ISREs. However, IFN-β did not induce
activation of p53, i.e., phosphorylation,
nor induction of p53 target genes in MEF.
Based on the general observations that
interferons have greater growth-inhibito-
ry activity on tumor rather than normal
cells, Takaoka et al. examined cells con-
taining the E6 human papilloma virus
(HPV) oncogene. In cells expressing
HPV E6, IFN-β increased p53 mRNA
and protein expression greater than in
normal MEF. The authors examined
colony formation of MEF transfected with
E6 + Ras and MEF p53−/− transfected
with Ras as a function of IFN-β concen-
tration. IFN-β reduced colonies of MEF
with E6 + Ras about 80% while reducing
colonies of MEF p53−/− with Ras only
about 10%. When they examined the
effect of IFN-β on apoptosis in X-ray-irra-
diated MEF transfected with the aden-
ovirus E1A protein, they found that
pretreatment of cells with IFN-β prior to
irradiation increased apoptosis from
about 50% to 95%, but had little effect on
nonirradiated cells. Studies with the
chemotherapeutic DNA-damaging agent
5-FU similarly showed that IFN-β
(10,000 unit/ml) with 5-FU decreased the
viability of HepG2 cells about 50% com-
pared to cells treated with 5-FU alone,
and only in cells with p53. All these
observations suggest that antitumor
activity of IFN-α and IFN-β is mediated at
least in part by p53.
To relate p53 to antiviral activity of
IFN-β, Takaoka et al. examined changes
in p53 in response to viral infection and
IFN-β. When cells were infected 
with vesicular stomatitis virus (VSV),
Newcastle disease virus (NDV), or her-
pes simplex virus (HSV), the quantity of
p53 protein and p53 phosphorylation
was increased and required an active
ATM kinase that phosphorylates p53. In
addition, some p53 target genes were
induced by viral infection (Mdm2, Puma),
but some other genes induced by DNA
damage were not (p21WAF1/Cip1, Noxa).
The results demonstrated that p53 is
activated, but virus infection and DNA
damage induced different target genes.
As expected, large levels of IFN-β were
produced during the viral infection.
Although on virus infection no increase
in p53 mRNA was seen in MEF 
IFNAR1−/− cells (cells lacking the recep-
tor for IFN-α and IFN-β), phosphorylation
of p53 did occur in MEF IFNAR1−/− cells,
indicating that activation of p53 is not
dependent on IFN-β. MEF infected with
VSV strongly undergo apoptosis, but
apoptosis was reduced in p53−/− MEF
and the virus yield was increased 30-
fold. Of great import was a single in vivo
experiment in mice. All p53−/− mice infect-
ed with VSV died within 16 days while
about 80% of wild-type mice survived.
Furthermore, the p53−/− mice had 100-
fold higher titer of VSV in serum. These
results allow several important conclu-
sions: the activation of p53 and the
induction of p53 are independent—IFN-β
only affects the induction, but does not
contribute to its activation; different tar-
get genes are induced by p53 in
response to DNA damage in comparison
to viral infection—a result that means
that induction of p53 genes can be mod-
ulated by other factors that are yet to be
discovered; and p53 is a significant regu-
lator of viral yield and ultimate fate of the
host in an infection.
Remarks
The data clearly support the authors’
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collaborations in tumor suppression and antiviral activities
In the recent paper by Takaoka et al. (2003), the authors demonstrate that interferons-α and -β stimulate p53 expression but
not p53 activation. The increase in p53 expression translates into significant enhancement of apoptosis and reduction of
chemotherapeutic dosages in vitro to destroy tumor cells. Furthermore, viral infections are also modulated by p53 in col-
laboration with interferons-α and -β. These observations are significant and may lead to new paradigms for therapy if the
high doses of interferon necessary to obtain the effects in vitro can be combined with more active interferons, interferons
with minimal side effects, and/or novel delivery systems to target interferons directly to tumors.
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conclusions: transcription of p53 is
induced by IFN-α and IFN-β; the higher
p53 levels enable increased apoptosis
by IFN-α and IFN-β; p53−/− mice suc-
cumb to VSV infection more readily than
wild-type mice. It would be anticipated
that most Type I IFNs (IFN-α, IFN-β, IFN-
ε, IFN-κ, IFN-ω, IFN-δ, and IFN-τ) will
induce p53 similarly, but, because they
often exhibit substantial differences in
activity (Pestka et al., 2004), there might
be significant variations. Takaoka et al.
(2003) will undoubtedly stimulate many
others to follow up in many avenues.
Nevertheless, many investigators have
concluded that other pathways link IFN-α
and IFN-β to apoptosis (Clemens, 2003),
so these apparent discrepancies will
need to be resolved.
Impact on cancer and viral therapy
Their results suggested that chemother-
apeutics and irradiation should be tried
in conjunction with interferons to mini-
mize doses and side effects. This has
been tried in clinical trials with spotty
results. However, the fact that the levels
of interferon Takaoka et al. (2003) used
in some experiments were as high as
10,000 unit/ml makes it unlikely that their
results could be simply translated to
patients because of intolerable side
effects. High levels of IFN-α are effective
in advanced melanoma, yet patients
often cannot tolerate the high doses
(Kirkwood, 2002). Nevertheless, IFN-α
and IFN-β have the innate power to
accomplish this, but it will take new chal-
lenging initiatives and technologies (e.g.,
sustained delivery systems, eliminating
side effects) to apply IFNs locally and
minimize the debilitating side effects of
systemic IFN (Lavoie et al., 2003). For
example, new interferons have been
developed that have higher activities
than the standard ones in clinical use
and could lessen side effects (Lavoie et
al., 2003; Pestka, 1998, 1999).
Furthermore, apoptosis is only one
aspect of cancer therapy with interferon.
The type I interferons exhibit a wide
breath of biological activities: antiviral,
antiproliferative, stimulation of cytotoxic
activity of many cells of the immune sys-
tem (T cells, natural killer cells, mono-
cytes, macrophages, dendritic cells),
increased expression of tumor-associat-
ed surface antigens, stimulation of MHC
class I antigens, induction and/or activa-
tion of proapoptotic genes and proteins
(e.g., TRAIL, caspases, Bak and Bax,
p53), repression of antiapoptotic genes
(e.g., Bcl-2, IAP [inhibitor of apoptosis
protein]), modulation of differentiation,
and antiangiogenic activity (Figure 1). All
these actions make interferon a most
promising agent to treat various dis-
eases, especially cancer and viral infec-
tions. The challenge is to be able to use
the enormous power of the interferons
without the debilitating side effects.
Appropriate technology to deliver the
interferons to tumors locally (Lavoie et
al., 2003; Mecchia et al., 2000) could
overcome the problem of systemic side
effects. Overall, it is highly likely that
interferons will play a major role in the
next generation of novel antitumor and
antiviral therapies. The enormous
progress in understanding how these
molecules (interferons, p53) function,
however, paves the way for their future
use in combating many maladies of
humanity.
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Figure 1. Antitumor actions of interferons
The actions of IFN-α and IFN-β that contribute
to their antitumor activity are shown in this
figure. These interferons act on the tumor
cells, the tumor stroma and cells of the
immune system that result in destruction of
tumor cells and tumors. Interferons help iden-
tify cancer cells to the immune system by
stimulating production of cell surface mole-
cules such as MHC complex antigens, tumor-
associated antigens (TAA), and
costimulatory molecules. Interferon also acti-
vates cells of the immune system (cytotoxic
lymphocytes, natural killer cells,
macrophages, monocytes, and dendritic
cells) that eliminate tumor cells throughout
the body. A summary of these actions is
shown in the figure.
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